Supernus Pharmaceuticals (SUPN) Inventory Average (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 15 years of Inventory Average data on file, last reported at $84.7 million in Q1 2026.

• On a quarterly basis, Inventory Average rose 63.38% year-over-year to $84.7 million in Q1 2026; TTM through Mar 2026 was $84.7 million, a 63.38% increase from a year earlier, with the FY2025 full-year figure at $68.3 million, up 3.78% from the prior year.
• Inventory Average for Q1 2026 stood at $84.7 million, up from $80.9 million in the prior quarter.
• Over the last five years, Inventory Average for SUPN reached as high as $91.3 million in Q1 2023 and fell as low as $46.7 million in Q2 2025.
• Historically, Inventory Average has averaged $76.1 million across 5 years, with a median of $80.9 million in 2025.
• Across the five-year window, Inventory Average jumped 77.32% in 2022 and sank 34.76% in 2025, its largest moves.
• Year by year, Inventory Average stood at $87.4 million in 2022, then retreated by 7.91% to $80.4 million in 2023, then retreated by 26.49% to $59.1 million in 2024, then jumped by 36.79% to $80.9 million in 2025, then rose by 4.74% to $84.7 million in 2026.
• Per Business Quant data, the three most recent Inventory Average figures were $84.7 million in Q1 2026, $80.9 million in Q4 2025, and $61.7 million in Q3 2025.